Predictive Biosciences Raises $25M in Series C Funding Round

The proceeds will be used to complete multi-center trials for Predictive's CertNDx bladder cancer diagnostic and for the commercial launch of the test through its CLIA certified laboratories, the company said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.